DDInter1538 DDInter1376
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Propofol {u} (Compound) resembles {v} (Compound) Fospropofol
Propofol {u} (Compound) treats {v} (Disease) epilepsy syndrome
Propofol {u} (Compound) binds {v} (Gene) CYP2B6
Propofol {u} (Compound) is included by {v} (Pharmacologic Class) General Anesthesia
Propofol {u} (Compound) downregulates {v} (Gene) NPDC1
Propofol {u} (Compound) causes {v} (Side Effect) Bronchospasm
Propofol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dyphylline
Propofol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Propofol (Compound) resembles Fospropofol (Compound)
Propofol (Compound) treats epilepsy syndrome (Disease)
Propofol (Compound) binds CYP2B6 (Gene)
Propofol (Compound) is included by General Anesthesia (Pharmacologic Class)
Propofol (Compound) downregulates NPDC1 (Gene)
Propofol (Compound) causes Bronchospasm (Side Effect)
Propofol may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Astemizole